Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by DigitalSpurson Apr 14, 2020 4:09pm

359 Views

Post# 30908913

RE:New video (Streamed an hour ago)

I love the fact that the CEO is very active; going out, doing interviews, representing the company and shareholders, while the scientists do their job to get things to the next level.

Really good feeling about this company! Well spoken, brief and lots of evidence.

Never goes overboard with promises to be number one, but states that they did outperform some leaders in the pharma space with their drug.

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal